23andMe Holding Co.

Equities

ME

US90138Q1085

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
0.4709 USD +6.11% Intraday chart for 23andMe Holding Co. -12.52% -48.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : 23andMe Holding Co., Q3 2024 Earnings Call, Feb 07, 2024
Earnings Flash (ME) 23ANDME Reports Q3 Revenue $44.7M, vs. Street Est of $56.3M MT
23andMe Holding Co. Reports Goodwill Impairment for the Third Quarter Ended December 31, 2023 CI
23andMe Holding Co. Provides Earnings Guidance for the Year Ending March 31, 2024 CI
23andMe Holding Co. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
23andMe Holding Co. Announces U.S. Food and Drug Administration Clears Investigational New Drug Application for 23ME-01473 CI
North American Morning Briefing : Big Tech Weighs on Stock Futures DJ
23andMe Holding Co. Announces Further Expansion of 23ME-00610 Phase 1/2a Clinical Trial in Advanced Neuroendocrine and Ovarian Cancer Patient Cohorts CI
23andMe Holding Co.(NasdaqGS:ME) dropped from S&P Health Care Services Select Industry Index CI
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Desktop Metal Poised to Rise, Ubiquiti to Decline MT
Alibaba Group Holds Stock in Nine U.S. Listed Companies MT
Transcript : 23andMe Holding Co., Q2 2024 Earnings Call, Nov 08, 2023
Earnings Flash (ME) 23ANDME Reports Q2 Revenue $50M, vs. Street Est of $56.8M MT
23andMe Holding Co. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
23Andme Holding Co. Reaffirms Earnings Guidance for the Year 2024 CI
23andMe Rolls Out New Prevention-Based Health Membership MT
23andMe Holding Co. Announces Updated Safety and Preliminary Efficacy Data from the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 CI
23andMe Holding Co. Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data CI
23andMe Holding Co. Amends the Original GSK Agreement CI
23andMe Holding, GSK Extend Partnership With $20 Million Data Licensing Agreement MT
23andMe Launches Service to Help Clients Manage Health Risks Hidden in DNA MT
23andMe notifies customers of data breach into its 'DNA Relatives' feature RE
US senator asks 23andMe for details after reported data for sale online RE
23andMe Shares Rally 12.7%, Ending 7-Day Losing Streak MT
Sector Update: Health Care Stocks Rising Late Monday Afternoon MT
Chart 23andMe Holding Co.
More charts
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4709 USD
Average target price
1.425 USD
Spread / Average Target
+202.61%
Consensus
  1. Stock
  2. Equities
  3. Stock 23andMe Holding Co. - Nasdaq
  4. News 23andMe Holding Co.
  5. Correction: Credit Suisse Starts 23andMe Holding at Outperform with $13 PT